quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:56:54·1617d
INSIDERFiling
Flexion Therapeutics, Inc. logo

SEC Form 4: Clayman Michael D. returned $9,541,675 worth of shares to the company (1,122,550 units at $8.50), closing all direct ownership in the company to satisfy withholding obligation

FLXN· Flexion Therapeutics, Inc.
Health Care
Original source

Companies

  • FLXN
    Flexion Therapeutics, Inc.
    Health Care

Recent analyst ratings

  • Nov 19UpdateNorthland Capital Markets-
  • Oct 19UpdateHC Wainwright & Co.$10.00
  • Oct 12UpdateBMO Capital$12.00
  • Oct 12UpdateRaymond James-
  • Oct 12UpdateCredit Suisse$10.00
  • Aug 6UpdateGoldman Sachs$6.00

Related

  • PR1409d
    Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
  • SEC1606d
    SEC Form 15-12B filed by Flexion Therapeutics, Inc.
  • SEC1610d
    SEC Form EFFECT filed by Flexion Therapeutics, Inc.
  • INSIDER1612d
    SEC Form 4 filed by Newtyn Management, Llc
  • INSIDER1612d
    SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
  • INSIDER1617d
    SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
  • INSIDER1617d
    SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
  • INSIDER1617d
    SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022